Integrated In Vitro Strategy for Accelerated Discovery of Sodium Channel Modulators for pain (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR270.16 / BB14; Pres time: Nov 17, 2026; 01:00 PM - 05:00 PM; Location: WCC Halls A-C; "The lead compound (VX-548) blocked hNav1.8 with an IC50 of around 0.3 nM and exhibited highly selectivity against other Nav isoforms ( Inhibition is less than 20% at 10μM)...T By integrating these orthogonal assays under uniform SOPs and analytics, the platform compresses hit-to-lead cycle time signicaicantly delivers directly comparable potency metrics across species and preparations, and provides a de-risking funnel that has already supported IND entry for Nav1.8 (and also other ion channel targets) programs. This cohesive, service-oriented pipeline offers a practical blueprint for bridging preclinical electrophysiology to clinical translation in pain therapeutics."
Preclinical • CNS Disorders • Pain • NAV1
|